Observation on the Clinical Treatment Effect of Chronic Pelvic Inflammatory Disease in Obstetrics and Gynecology
Abstract
Objective: To explore the effectiveness and related methods of clinical treatment of chronic pelvic inflammatory disease in obstetrics and gynecology. Method: An experiment was conducted on patients with chronic pelvic inflammatory disease who received treatment from a certain hospital in China from December 2021 to December 2022. Forty patients were randomly selected and divided into a control group and an experimental group, with 20 patients in each group. Among them, the control group was treated with conventional methods for chronic pelvic inflammatory disease, while the experimental group was treated with Kangfu Xiaoyan Suppository based on conventional therapy. The final total effective rate, six-month recurrence rate, and incidence of adverse reactions were compared between the two experimental groups after receiving clinical treatment. Result: After receiving treatment, the total effective rate of the experimental group was 100%, while the total effective rate of the control group was 70%. The difference between the two groups was statistically significant (P>0.05); The incidence of adverse reactions in the experimental group was 15%, while the incidence of adverse reactions in the control group was 25%. The difference between the two was statistically significant (P>0.05); The recurrence rate within six months in the experimental group was 25%, while the recurrence rate within six months in the control group was 50%. The difference between the two was statistically significant (P>0.05). Conclusion: In clinical practice, patients with chronic pelvic inflammatory disease are treated with Kangfu Xiaoyan Suppository based on routine treatment. The application of this treatment method does not cause serious adverse reactions, and can effectively alleviate the patient's condition and reduce the recurrence rate of the disease within six months. It is a particularly ideal treatment method that can fundamentally reduce the effective time of patient treatment.
References
Quan JN. Meta analysis of the efficacy and safety of Fuke Qianjin Tablets combined with Levofloxacin and Metronidazole in the treatment of chronic pelvic inflammation. Journal of Clinical Rational Drug Use, 2021.
Wei TY. The effect of Jingangteng capsules combined with gynecological Qianjin tablets on the efficacy and immune function of patients with chronic pelvic inflammatory disease. China Minkang Medicine, 2021.
Song J. Clinical effect of Fuke Qianjin Tablets combined with Fosfomycin tromethamine on chronic pelvic inflammatory disease. Journal of Practical Clinical Medicine, 2021.
Hao LF. Effect of Fuke Qianjin Tablets combined with Metronidazole on serum inflammatory factors and immune function in patients with chronic pelvic inflammation. Chinese Folk Therapy, 2021.
Liu JM. Observation on the clinical treatment effect of chronic pelvic inflammatory disease in obstetrics and gynecology. Practical Medicine in China, 2021.
Copyright (c) 2023 Wenzhi Wang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
